Get started

Stocktrading

S&P 500 ($SPY) COLLAPSE | Recession Alert!!Behold, devastation just up ahead. $2500 is probable in the S&P. Retirements are about to be wiped out. As a friendly reminder, the "401K is free money" narrative is going to evaporate. The media will soon be out in full force talking about: "stay the course" "remember your goals" "stay invested" "LFG" "buy the dip" So foolish. If you are trapped in a retirement fund (401K), the best thing you can do right now is get defensive. Sell ALL "growth stocks" and shift all of your wealth into cash and / or bonds. Be careful out there, everyone! Something major is happening on a global scale!
TVC:SPXShort
by ChiefMacro
9
Raj Rayon : {"Potential for Best investment for 2024";} We are at the Biggest Picture available as per the data; Price has formed a Wave 1 which is an Impulse Wave In the Upward direction; Wave 2 is a downward 3-Wave-Simple-Correction Structure, retracing Wave 1 by less than a 100% which suffices the Laws of Wave as per the Elliott Wave Theory and now. ====================================================================== Let's talk about the most interesting part The Most Awaited Wave 3 is expected to come out, showing the move which is the reason why we trade, According to the Elliot Wave Theory the Projection of Wave 3 is at least 161.80% of the Wave 1. Let's see on the charts the Extension Levels as per the Best Leading Indicactor Fibonacci Extension; Yo !!!! Now Last Month that's in August 24, Price has closed above the EMA and hence I see a Buying Momentum in the Monthly chart, Looking at the Promotor Holding of this company which is more than 90% only confirms my belief in the future growth of the company. So we have an Overall Target Projection of Rs. 158.03 {Derived as per Fibonacci Extension} Now Let's look at the other side the {downside/ stop loss/ risk against the reward}
NSE:RAJRILTDLong
by WavesandZones
Sunrun (RUN) AnalysisCompany Overview: Sunrun is a leading U.S. residential solar energy company, providing solar panel installations and energy services across the country. The company's focus on sustainable energy solutions positions it to capitalize on the growing shift toward clean energy adoption. Key Catalysts: Rate-Cutting Cycle: A potential rate-cutting cycle by the Federal Reserve could make solar financing more affordable, increasing the economic appeal of residential solar projects. Lower interest rates would reduce borrowing costs for consumers, making Sunrun's solar installations more accessible and boosting sales. Trade Policies: U.S. Treasury Secretary Janet Yellen's scrutiny of China's market practices, particularly regarding solar products, could mitigate low-cost competition from Chinese manufacturers. This would benefit domestic companies like Sunrun by leveling the playing field and potentially driving higher demand for U.S.-installed solar systems. Federal Subsidies: Sunrun is well-positioned to benefit from federal clean energy subsidies provided by the Inflation Reduction Act (IRA). These subsidies are expected to reduce Sunrun's operating expenses and enhance profitability by offsetting costs associated with installations and energy storage solutions. Investment Outlook: Bullish Outlook: We are bullish on NASDAQ:RUN if it holds above the $17.50-$18.00 range. Upside Potential: The upside target for Sunrun is set at $29.00-$30.00, driven by favorable interest rate conditions, supportive trade policies, and federal clean energy subsidies. ☀️ Sunrun—ready to shine with rate cuts, trade advantages, and clean energy subsidies! #RUN #SolarEnergy 🚀🌱
NASDAQ:RUNLong
by Richtv_official
1
Sea Limited (SE) AnalysisCompany Overview: Sea Limited, a global consumer internet company, operates across three core businesses: e-commerce (Shopee), digital entertainment (Garena), and financial services (SeaMoney). The company has returned to growth investments to capitalize on its diverse business segments. Key Catalysts: E-commerce Momentum: Shopee's gross merchandise volume (GMV) forecast has been revised upward to reflect mid-20% growth, indicating strong momentum in its e-commerce segment. This renewed growth suggests that Sea's strategic investments are yielding positive results, particularly in expanding its reach across Southeast Asia and Latin America. Gaming Recovery: Garena's flagship game, Free Fire, has seen a 19% year-over-year rebound in daily active users. This recovery signals a resurgence in the gaming division, which has long been a key revenue driver for Sea. Additionally, a potential relaunch of Free Fire in India could provide a significant boost, given the large gaming audience in the country. Revenue Growth Outlook: Sea Limited is forecasting double-digit revenue growth for 2024, driven by Shopee's expansion, Garena's gaming resurgence, and the ongoing scaling of SeaMoney. Investment Outlook: Bullish Outlook: We are bullish on NYSE:SE if it holds above the $67.00-$68.00 range. Upside Potential: The upside target for Sea Limited is set at $130.00-$135.00, driven by continued e-commerce growth, gaming recovery, and potential entry into new markets. 🌊 Sea Limited—e-commerce growth and gaming rebound fuel bullish outlook! #SE #Ecommerce #Gaming 🚀📈
NYSE:SELong
by Richtv_official
Does Solana will continue their bounce play more than 45% !!Solana has gained more than 45 % from last fall down that was in 5th August 2024 the trend right now is inside the range ( Phase C - Wyckoff Method ) The far target is 216 ( Top of the side way range) if the Re-accumulation phase has succeed. SL is 141.46 ( this for me is consider thin stop loss due to the high BINANCE:SOLUSDT volatility of the crypto market) I am Just sharing insights and market trends for learning and growing every day and it is not financial advice.
Long
by FSelim55
4
TEVA Pharmaceutical is a BUY?As the excitement around AI continues to wane, concerns about a potential US recession grow, and the risks of a major conflict in the Middle East linger, Teva Pharmaceutical's stock is entering an accumulation phase above $18, signaling strong bullish sentiment. Why Wall Street's bullish in this drug company ? First, on July 31, Teva announced its financial results for the second quarter of 2024, demonstrating that the company remains resilient despite years of investor disappointment following the Allergan Generics acquisition and the loss of Copaxone exclusivity. However, over the past 18 months, under Richard Francis' leadership, the company has shown significant growth, with increasing revenue and profits in its European and US segments, the successful launch of biosimilars and Uzedy, and record sales of Austedo, its blockbuster treatment for certain neurological disorders. Alongside rising sales of generics, Teva has also accelerated the development of innovative medications, which could set new standards in treating schizophrenia and some chronic inflammatory diseases. For instance, on July 25, the company delighted investors by announcing that it had completed patient enrollment ahead of schedule in a Phase 2b clinical trial assessing the efficacy and safety of duvakitug for treating ulcerative colitis and Crohn's disease, driven by strong interest from healthcare professionals and patients. Teva Pharmaceutical's financial performance and 2024 outlook After years of challenges, the Teva revenue exceeded $4 billion once again, reaching $4.14 billion in the second quarter of 2024, a 7.4% year-on-year increase that surpassed consensus estimates by $114 million. Meanwhile, another critical financial metric, earnings per share aka EPS, exceeded my expectations despite rising costs associated with conducting expensive clinical trials for assessing the efficacy of Teva's biosimilars and experimental drugs targeting neurodegenerative and autoimmune disorders. The Israeli company's EPS reached $0.61 for the three months ending June 30, 2024, marking a 27.1% increase from the previous quarter and surpassing analysts' forecasts by six cents. What factors contribute to Teva Pharmaceutical's success? To answer this objectively, it's essential to examine not only the impact of sales from individual medications but also to delve deeper into how effectively the company's management is handling the development of each of Teva's business segments. We'll begin with the United States segment, which significantly influences Teva's financial standing. For the three months ending June 30, 2024, revenue in this segment reached $2.12 billion, reflecting an 11.5% year on year increase and a 22.3% rise from the previous quarter. First, Teva's revenue and profit growth were largely fueled by significant advancements in its generics business, despite facing stiff competition from companies like Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Perrigo (PRGO), and others in the market. In the second quarter, total sales of generic products reached approximately $1.03 billion, marking a 26.6% increase from the previous quarter. What factors led to the recovery of Teva's generics business? The resurgence of Teva's generics business in the U.S. was primarily driven by the launch of an interchangeable biosimilar to AbbVie's Humira (ABBV), rising demand for generic versions of Bristol-Myers Squibb's Revlimid (BMY), a major blockbuster for treating multiple myeloma, the generic version of Novo Nordisk's Victoza (NVO) for type 2 diabetes, and the expansion of its drug portfolio. The soaring sales of Copaxone and the strong performance of Austedo, which I analyzed in detail in a previous article, were also notable. Despite increasing competition in the U.S. tardive dyskinesia therapeutics market from Neurocrine Biosciences' (NBIX) Ingrezza, Austedo's demand continued to grow. Sales of the Austedo franchise reached $407 million in the second quarter of 2024, a 32.1% YOY increase, driven by expanded patient access and the FDA's late May approval of Austedo XR in four new tablet strengths, giving doctors more options for optimizing treatment regimens for adults with tardive dyskinesia and Huntington's disease-associated chorea. I also want to highlight Uzedy, a long-acting formulation of risperidone, as another key contributor to Teva's revenue growth. Although the company launched Uzedy in May 2023 and has not yet disclosed its sales figures, it has been approved for the treatment of schizophrenia. However, as evident from the chart below, the total number of prescriptions has been steadily increasing month over month. Teva Pharmaceutical estimates that its revenue from Uzedy will be around $80 million in 2024, exceeding my expectations by approximately $25 million. Despite ongoing growth in demand for this anti-CGRP migraine medication, its sales amounted to $42 million in the second quarter of 2024, a decrease of 6.7% compared to the previous quarter and 19.2% year-on-year. This decline was primarily due to an increase in sales allowances linked to a one-time event. Now, let's turn our attention to the company's Europe segment, which generates most of its revenue through sales of generics and biosimilars. For the three months ending June 30, 2024, sales in this segment reached approximately $1.21 billion, reflecting a 4.3% year-on-year increase, driven by new product launches and growing demand for Ajovy. However, sales of respiratory medications continue to face challenges due to a decline in cold and flu cases. As anticipated, demand for Copaxone is weakening, not only because of competition from generic versions but also due to the availability of more effective treatments for relapsing forms of multiple sclerosis, such as Bristol-Myers Squibb's Zeposia, Roche Holding's Ocrevus and TG Therapeutics' Briumvi (TGTX). Lastly, let's discuss the International Markets segment, which focuses on commercializing Teva's drugs across 35 countries, including Canada and Japan. In the second quarter, revenue for this segment was $593 million, representing a 2.6% YOY increase. However, the segment's profit dropped significantly to $73 million quarter over quarter, due to declining demand for Copaxone, increased R&D expenses, and higher sales and marketing costs related to the distribution of Austedo in China. The question arises: "Are there any positives?" The short answer is yes. Teva's revenue from generic drugs has been on an upward trend in recent years, with the exception of the fourth quarter of 2023. For the three months ending June 30, 2024, it reached $488 million, marking a 2% increase from the previous quarter. What is driving this sales growth? Despite challenges such as the weakening of foreign currencies like the Japanese yen, ruble, and Chinese yuan against the US dollar, increased competition in Japan, and ongoing inflationary pressures on the pharmaceutical industry, Teva’s management has successfully navigated these obstacles by expanding its medication portfolio and raising prices. Now lets talk about Risks Several risks could negatively impact Teva Pharmaceutical’s investment appeal in the medium to long term. At the end of July, Teva reported financial results for the second quarter of 2024, which not only exceeded analysts' expectations but also reinforced confidence in the effectiveness of the business strategies implemented by CEO Richard Francis. In addition to accelerating the recovery of the company's generics business, boosting sales of Austedo and Uzedy, and launching the Humira biosimilar in May, Teva also raised its full-year 2024 guidance. With a P/E ratio of 6.35x, which suggests the stock is trading at a discount compared to the broader healthcare sector, other positives include the reduction of Teva’s net debt by about $2 billion over the past 12 months, as well as year-over-year growth in gross and operating profits. To understand who truly holds control over Teva Pharmaceutical Industries Limited, it's crucial to examine the company's ownership structure. The largest share of ownership, approximately 69%, is held by institutional investors. This means that this group stands to experience the greatest potential for gains or losses, depending on the company's performance. The company has also accelerated the development of its product candidates under its "Pivot to Growth" program, which aims to strengthen its balance sheet and enhance its investment appeal by expanding its biosimilar portfolio and bringing potential best-in-class drugs for cancer, neurological, and autoimmune disorders to market. So TEVA Pharmaceutical is a BUY? YUP
NYSE:TEVALong
by moonypto
Teva Pharmaceuticals (TEVA) Analysis Company Overview: Teva Pharmaceuticals, a global leader in generics and specialty medicines, is poised for growth as it expands its biosimilar portfolio and resolves major legal challenges. Key Catalysts: Biosimilar Launch: NYSE:TEVA plans to launch AVT04, a biosimilar to Johnson & Johnson's blockbuster drug Stelara, by February 2025. Stelara, which generates $10 billion in annual sales, presents a significant market opportunity for Teva as a lower-cost alternative. This biosimilar could drive substantial revenue growth for the company. Opioid Settlement: The resolution of the $4.3 billion opioid settlement reduces legal uncertainty and allows Teva to focus on business expansion. This development provides a clearer path forward for the company’s financial health. Operational Improvements: With improved supply chains and enhanced gross margins, Teva is positioned to strengthen profitability. This operational efficiency will be crucial in boosting the company's bottom line as it rolls out new products. Investment Outlook: Bullish Outlook: We are bullish on TEVA if it holds above the $15.50-$16.00 range. Upside Potential: The upside target for Teva Pharmaceuticals is set at $23.00-$24.00, driven by the upcoming biosimilar launch, legal clarity, and improved operational performance. 💊 Teva Pharmaceuticals—biosimilar potential and legal resolution set to unlock growth! #TEVA #Pharma 🚀📈
NYSE:TEVALong
by Richtv_official
Nvidia Stock Soars On Blowout GuidanceSoaring demand for the chips needed to train the latest wave of generative artificial intelligence systems such as ChatGPT led Nvidia to issue a revenue forecast far ahead of Wall Street expectations, prompting a surge in its stock price in after market trading. The US chipmaker on Wednesday said it expected sales to reach 11bn dollar in the three months to the end of July, more than 50 per cent ahead of the 7.2bn dollar analysts had been expecting and confirming its position as the biggest short-term beneficiary of the AI race that has broken out in the technology industry. The forecast fuelled a 27 per cent leap in Nvidia’s shares, which had already more than doubled since the start of the year, and lifted its stock market value to a record 960 bn dollar. Jensen Huang, chief executive, said the company was “significantly increasing our supply to meet surging demand” for its entire family of data centre chips, including the H100, a product launched this year that was designed to handle the demands of so-called large language models such as OpenAI’s GPT4. The race in the tech industry to develop larger AI models has led some customers to worry privately about a shortage of H100 chips, which only went on sale earlier this year. However, Nvidia’s $4.28bn in sales to data centre customers in its latest quarter topped even the most optimistic analysts’ forecasts, and the company said there had been strong sales of both the H100 and its A100 chips, based on its previous chip architecture. Nvidia’s forecast noted a potential doubling of sales to data centre customers in three months, even though data centre sales were running at an annualised rate of $17bn in the opening quarter of this year. Growth is coming from customers across the board, Kress said, with consumer internet companies, cloud computing providers and enterprise customers all rushing to apply the generative AI to their businesses. The bullish forecast came as Nvidia reported revenue and earnings in its latest quarter, to the end of April, had also topped forecasts, thanks to a jump in sales to data centre customers as demand for AI took off. Revenue reached $7.19bn, up 19 per cent from the preceding three months but down 13 per cent from the year before, as sales of chips for gaming systems dropped. Earnings per share rose 22 per cent from a year before to 82 cents, or $1.09 on the pro forma basis Wall Street judges the company. The consensus view on Wall Street had been for revenue of $6.52bn and pro forma earnings of 92 cents a share. now let's delve into the numbers. Nvidia's different business units did not all perform equally well during the quarter - which can be expected, of course. Nvidia's data center business grossed revenues of $4.3 billion during the first quarter, which represents a new record high. Data center demand is not very cyclical, and companies kept investing in new equipment despite a potential recession being on the horizon. This can be explained by the fact that data centers are mission critical for many companies, so they don't really have a lot of choice when it comes to allocating capital to this space. Strong data center sales also have been seen in the results of other chip companies such as Advanced Micro Devices (AMD). Both Nvidia and AMD also were able to benefit from the weak performance of their competitor Intel (INTC), as Intel has been losing market share in the data center space in recent quarters due to self-inflicted problems and an unconvincing product line-up. Nvidia is a major graphic chip or GPU player and is thus heavily impacted by the performance of related end markets. This includes both cryptocurrency mining and gaming. While some cryptocurrencies can't be mined with GPUs economically, such as Bitcoin, others, such as Ethereum, can be mined with GPUs. Ethereum moved from a proof-of-work model to a proof-of-stake model in the fall of 2022, but some miners still use GPUs for Ethereum mining. Not surprisingly, Nvidia's sales to this end market depend on the price for cryptocurrencies - when cryptocurrencies are expensive, miners are more eager to acquire additional GPUs and they may also be willing to pay high prices for them. During times when cryptocurrencies are less expensive, mining is less profitable, and GPU demand from cryptocurrency miners wanes. This has had an impact on Nvidia's sales in the past and likely played a role in Nvidia's Q1 sales as well. GPU sales have been under pressure in recent quarters due to lower demand by gamers as well. Many that like to play video games upgraded their hardware during the lockdown phase of the pandemic when staying at home meant that consumers had more time for video games. With many gamers having relatively new equipment, demand has declined in the recent past. At the same time, inflation pressures consumers' ability to spend on discretionary goods. On top of that, some consumers prefer to spend their money on experiences over things now as there are no lockdowns or travel restrictions in place any longer. All in all, this has resulted in a difficult macro environment for Nvidia's gaming business. Combined, the headwinds for the gaming market and the cryptocurrency market explain why Nvidia's sales and profits kept declining during the most recent quarter, relative to the results the company was able to generate one year earlier. The strong performance in the data center space was not enough to offset the headwinds Nvidia experienced in other areas. I personally going to take huge profit right now and wait for 250 $ levels
NASDAQ:NVDA
by moonypto
5
Coal India bullish swing expectedCoal India is a potential stock which can breakout & can give a good move. Its trading at its resistance on daily time frame. If breaks resistance then min expectation will be 600. its a under valued stock having a P.E 8.97 so can be preffered for long term investment also. Disclaimer: Any of my posts should not be considered as a Buy/ Sell/Hold recommendation. This analysis is for educational and learning purpose only. I always recommend using Stop Loss and following risk management rules.
NSE:COALINDIA
by jain_abhishek
1
SWING IDEA - PETRONET LNGThis presents an attractive opportunity for swing traders to capitalize on the potential uptrend in Petronet LNG . Reasons are listed below : Breakout of Strong Resistance at 300 : Petronet LNG has successfully broken above a significant resistance level at 300, signaling potential bullish momentum. Bullish Marubozu Candle on Weekly Timeframe : The presence of a bullish Marubozu candlestick pattern on the weekly timeframe suggests strong buying momentum and potential upward movement. Breakout from 6+ Years of Consolidation : The stock has broken out from a consolidation phase lasting over 6 years, indicating a significant shift in market sentiment and potential for sustained upward movement. Trading Above 50 and 200 EMA : Petronet LNG is trading above both the 50 and 200 Exponential Moving Averages (EMA), confirming bullish bias and indicating potential for trend continuation. Support from 0.382 Fibonacci Level : Finding support at the 0.382 Fibonacci level and bouncing back reinforces the bullish outlook and provides a solid foundation for potential upward movement. Trading at All-Time High (ATH) : Petronet LNG is trading at its all-time high, indicating strong bullish momentum and potential for further gains. Constant Higher Highs : The stock consistently forms higher highs, reflecting increasing bullish momentum and reinforcing the potential for further gains. Target - 340 // 380 Stoploss - weekly close below 260 DISCLAIMER - Decisions to buy, sell, hold or trade in securities, commodities and other investments involve risk and are best made based on the advice of qualified financial professionals. Any trading in securities or other investments involves a risk of substantial losses. The practice of "Day Trading" involves particularly high risks and can cause you to lose substantial sums of money. Before undertaking any trading program, you should consult a qualified financial professional. Please consider carefully whether such trading is suitable for you in light of your financial condition and ability to bear financial risks. Under no circumstances shall we be liable for any loss or damage you or anyone else incurs as a result of any trading or investment activity that you or anyone else engages in based on any information or material you receive through TradingView or our services. @visionary.growth.insights
NSE:PETRONETLong
by Visionary_Growth_Insights
10
Morepen Laboratories Trading IdeaIntroduction Morepen Laboratories Ltd. engages in the business of manufacturing bulk drugs, intermediates, and medical devices; and business of formulation. It operates through the following geographical segments: the United States of America, Rest of World, and India. Observation Stock Trade all the Ema making rounding bottom after a rejection from 72 level in 2021. now it is trying to breakout the same level once it breakout and sustain above 72 level no one can stop this stock to reach my levels which is 120. on weekly chart you'll see a gap up open marubozu candlestick stock look strong on all the TF. Get the inside scoop! Read the rest of the article on our blog 👆
NSE:MOREPENLABLong
by SHEHBAZ_KHAN
2
CarGurus (CARG) AnalysisCompany Overview: CarGurus, a leading online platform for buying and selling cars, continues to attract investor confidence with its growing user base and strong market positioning. The platform's ability to connect consumers with dealers is driving its popularity, making it a significant player in the automotive marketplace. Key Highlights: Rising User Engagement: CarGurus saw a 3% increase in average monthly users, a strong indicator of consumer engagement and platform relevance. This growth reflects the company's effectiveness in attracting and retaining users, crucial for long-term success. Analyst Optimism: Analysts are bullish on CarGurus' prospects. JPMorgan Chase & Co. raised their target price to $32.00, while BTIG Research set theirs at $30.00, both maintaining a "Buy" rating. This analyst confidence highlights the market's positive view of CarGurus' growth trajectory. Revenue Growth: The company's Marketplace business reported its largest quarterly revenue increase since 2021. This growth was driven by higher adoption of add-on products, a shift to premium service tiers, and expansion of its global dealer base, all contributing to stronger financial performance. Investment Outlook: Bullish Outlook: We are bullish on NASDAQ:CARG above the $23.00-$24.00 range. Upside Potential: With an upside target of $35.00-$36.00, CarGurus presents a compelling growth opportunity as it continues to enhance its platform, expand its dealer network, and increase user engagement. 📈🚗 CarGurus—driving growth and accelerating your portfolio! #CARG #Automotive 🚗💼
NASDAQ:CARGLong
by Richtv_official
TSLA / TESLATSLA (Tesla, Inc.) Stock Analysis: Key Dates and Potential Market Movements: 1. August 23, 2024 - Potential Upside: • Scenario: The chart indicates a potential bullish movement around late August 2024. This could be driven by positive earnings reports, advancements in Tesla’s technology, or an increase in market optimism around Tesla’s leadership in the EV market. • Impact on Price: We might see a short-term rally in Tesla’s stock price, pushing it towards previous highs around the $270 mark. 2. October 15, 2024 - Potential Downside: • Scenario: As we approach mid-October 2024, the chart suggests a potential bearish phase. This could be due to broader market corrections, profit-taking by investors, or any negative news related to supply chain disruptions or increased competition in the EV market. • Impact on Price: Tesla’s stock could see a pullback, potentially testing support levels around $215 or even lower. 3. February 19, 2025 - Recovery Phase: • Scenario: By early 2025, the chart indicates a recovery phase, possibly due to strong Q4 2024 earnings, the introduction of new Tesla models, or significant advancements in battery technology. • Impact on Price: This period might mark the beginning of a new bullish trend, with Tesla’s stock price climbing back towards the $250-$300 range. 4. May 9, 2025 - Consolidation or Continued Growth: • Scenario: The market could enter a consolidation phase, where the stock trades within a range, or Tesla could continue its growth trajectory depending on the broader economic conditions and Tesla’s performance. • Impact on Price: If the market conditions are favorable, Tesla might break out to new highs; otherwise, we could see sideways movement in the $250-$300 range. 5. September 4, 2025 - Potential Market Shift: • Scenario: As we approach late 2025, the chart suggests another critical phase, potentially influenced by macroeconomic factors, such as changes in interest rates or shifts in consumer demand for EVs. • Impact on Price: This could lead to either a breakout to new highs or a retest of lower support levels, depending on the prevailing market sentiment. 6. December 4, 2025 - Year-End Rally: • Scenario: The end of 2025 could see a year-end rally, driven by strong sales numbers, holiday season demand, or favorable policy decisions regarding EV subsidies. • Impact on Price: Tesla’s stock might experience a strong rally, potentially setting new highs or revisiting levels around $300. Considerations for Investors: • Technological Advancements: Tesla’s continued innovation in battery technology, autonomous driving, and energy solutions could be key drivers of its stock price. • Market Sentiment: Investor sentiment around the EV market and broader technology sector will play a crucial role in Tesla’s stock movements. • Geopolitical and Economic Factors: Changes in global trade policies, supply chain disruptions, and shifts in consumer demand could impact Tesla’s performance. Given the potential market shifts and Tesla’s leadership in the EV space, are you considering adding Tesla to your portfolio? How do you see Tesla’s position evolving as we approach key market dates in 2024 and 2025?
NASDAQ:TSLA
by trushkovskiy